Inter-assay variability in the degree of platelet inhibition following GPIIb/IIIa receptor blockade in patients undergoing coronary intervention: a comparison of three different point-of-care assays  by Soffer, Daniel et al.
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and Group N (n=11). However, AISV was significantly less in Group P than in Group N 
(4.9~:5.2 vs. 13.8+12.3 mm 3, p=0.03). Less ~VV tended to be associated with greater 
AISV although this correlation did not reach statistical significance (r=0.26, p=0.22). 
Conclusions: The IVUS substudy of PREVENT demonstrated a variable degree of ves- 
sel remodeling exterior to the coronary stent during the follow-up period. In addition to 
the direct anti-proliferetive effect of brachytherapy, the positive pad-stent remodeling may 
be another contributing factor to intrastent neointimal suppression following beta irradia- 
tion. 
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887-2 Inter-Aeaay Variability in the Degree of Platelet 
Inhibition Following GPIIb/Illa Receptor Blockade in 
Patients Undergoing Coronary Intsrventlon: A 
Comparison of Three Different Point-of-Care Assays 
Daniel Softer. William W. O'Neill, Kishore J. Harlai, Simon R. Dixon, Judith Bouts, Robert 
D. Safian, Cindy L. Grines, lasam Mouasa, Gary S. Roubin, Jeffrey W. Moses, William 
Beaumont Hospital, Royal Oak, Michigan, Lenox Hill Heart and Vascular Institute, New 
York, New York. 
Background: The degree of platelet inhibition (PI) induced by GPIth/llla antagonists has 
been shown to influence clinical outcomes following percutaneous coronary intervention 
(PCI). There is no comparative data on the degree of PI using different commercially 
available point-of-care PI assays. 
Methods: We prospectively enrolled 24 pts (66 ± 10 yrs, 18 males) who received a 
GPifb/llla inhibitor during PCI. Pts received tirofiban; n=15 (10mcg/kg, 0.15mcg/kg/min), 
eptifibitide; n=7 (single bolus; 180mcg/kg, 2mcg/kg/min), and abciximab; n=2 (0.25mg/ 
kg, 0.125mcg/kg/min). We compared the degree of PI using 3 different assays: 1) 
20p.mol ADP/citrate in the IchorTM piatelet analyzer (Helena Laboratories, Beaumont, 
TX), 2) iso-TRAP/citrate and 3) iso-TRAP/PPACK as piatelet agonists/enticoaguiants 
respectively in the UltagraTM system (Accumetrics, San-Diego, CA). PI was measured in 
all pts 30 min following GPIIb/llia bolus, with each assay performed on the same blood 
sample. 
Results: The mean ± SD values of PI following GPIIb/Itia administration are shown 
below. 
Conclusion: There is significant variation in the degree of PI assessed by the three 
assays. The greater inter-patient variability and the lower mean PI, detected by the 
IchorTM system may enhance patient stratification based upon response to GPIIb/llla 
inhibitors. The practical implications of these findings need to be validated in large-scale 
clinical outcome trials. 
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887-1 Elevated Troponin Following Percutaneous Coronary 
Intervention Predicts Subsequent Events: Results From 
the ESPRIT Trial 
Christoeher K. Dyke. Danny K. Benjamin, Jr., Charlotte L. Nelson, Kdstin Newby, Conor 
O'shea, Warren Cantor, Can Nguyen, John H. Alexander, Michael M. Kitt, James E. 
Tcheng, Duke Clinical Research Institute, Durham, North Carolina. 
Background: Few data exist to assess the significance of troponin following stent percu- 
tanecus coronary intervention (PCI). We examined the predictive utility of post-PCI tropo- 
nin for subsequent cardiac events in the ESPRIT trial. Methods: Troponin was measured 
in local laboratories at the discretion of the site investigator. Of participants that had a 
post-PCI troponin (n=392), 52 were excluded due to an endpoint of death or MI (core CK- 
MB 3X upper limit of normal (ULN)) at 48 hours. In the remaining population (n--341), we 
assessed the relation of troponin elevation to occurrence of the ESPRIT-defined compos- 
ite of death, MI, and TVR to 365 days in a Cox proportional-hazards (PH) model. We 
dichotomized (<=ULN or >ULN) troponin and included it as a time-dependent covadate. 
Results: The baseline characteristics were similar in the overall tdal population (n=2064), 
participants with post-procedure troponin measured (n=341), and participants with an 
elevated (n=123) or normal (n=218) tmponin. An elevated post-PCI troponin was associ- 
ated with a 3-fold higher risk for subsequent cardiac events (HR-.-.-~.97;p=0.019). These 
results did not differ significantly with troponin >3X ULN in the time to event model. Con- 
clusion: In a low-risk patient population undergoing elective PCI, an elevated post-PCI 
troponin >ULN was associated with a significant increase in subsequent cardiac events. 
Development of strategies to prevent even minor myocardial necrosis as detected by 
troponin post-PCI is warranted. 
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887-3 Point-of-Care Measurement of Platelet Function Before 
Angioplasty Strongly Predicts Future Target Veuel 
Reveacularization 
Steven R. Steinhubl. Jorge F. Saucedo, David C. Sane, Peter B. Berger, David J. 
Molitemo, James E. Tcheng, Dean J. Kereiakes, Wilford Hall Medical Center, San 
Antonio, Texas, Lindner Research Center, Cincinnati, Ohio. 
Background: Baseline plateiat activation correlates with the need for target vessel revascularo 
ization (TVR) following PCI but is of limited clinical ~lity due to the need for specialized test- 
ing. The Ultegra-RPFA is a simple, point-of-care assay approved for use in monitoring 
plateiet function in patients treated with GPIIb/llia antagonists that also quantifies the 
patient's baseline platelet function. 
Method: As part of the GOLD study, baseline Platslet Activation Units (PAU) were measured 
using the Uitegra-RPFA in 500 patients undergoing a pemutanecus coronary intervention 
with the adjunctive use of a GPIII:YlIla antagonist. TVR at 7 months was evaluated in a subset 
of 194 abciximab-treatad patients and analyzed with respect to baseline platelet function. 
Results: Baseline plateiet function ranged from 52 to 471 PAU (median 234). Patients with 
the lowest PAU values at baseline, consistent with more activated or "exhausted" platelets 
had a significantly greater risk of TVR than those paitents with highest baseline PAU levels 
(Figure). 
Conclusion: These results confirm that increased levels of plateiet a~vation prior to PCI are 
assooated with an increased risk of TVR, and confirm that this can now be easily determined 
utilizing a simple point.of-care assay. Routine platelet function monitoring may help to opti° 
mize the future use of more expensive therapies designed to prevent restenosis. 
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